Business
Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Late-Breaking Presentation Highlighted Positive18-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients SAN
About this update from Capricor Therapeutics, Inc.
[{"type":"text","content":"Late-Breaking Presentation Highlighted Positive18-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients\nSAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company presented the 18-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD) at this year’s Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, which took place virtually and in-person in Dallas, Texas from March 19-22, 2023. Dr. Craig McDonald, national Principal Investigator and University of California, Davis, Professor and Department of Physical Medicine and Rehabilitation Chair, presented the findings during a late-breaking session. Key results from the study, include: Statistically significant differences in the Performance of the Upper Limb (PUL version 2.0) scale in the CAP-1002 original treatment group when compared to the original placebo group from HOPE-2 (p=0.02). Both groups experienced reduced disease progression once all patients began treatment in the OLE study.CAP-1002 treatment during the OLE portion of the study continues to yield a consistent safety profile and has been well-tolerated throughout the study.The HOPE-2 OLE study previously met the primary endpoint at the one-year time-point and these 18-month results suggest that patients accumulate benefit over time with preservation of skeletal muscle function, which underscore the potential long-term benefit of CAP-1002. “There are thousands of boys and young men across the world who continue to face the devastating and immobilizing effects of DMD, and for whom few therapeutic options currently exist,” said Dr. Linda Marbán, CEO of Capricor. “Our 18-month results suggest that CAP-1002 has the potential to slow the decline of DMD progression and speaks to the long-term benefit for patients. We were pleased to present these results alongside other industry leaders who share Capricor’s mission of developing novel treatments for patients suffering from rare neuromuscular conditions.” Capricor is currently conducting the...